“Foreign dependencies” exist in several steps of the medical radioisotope supply chain, threatening the EU’s strong position in production and endangering the development and application of nuclear medicine products and procedures, the annual report of the Euratom Supply Agency (ESA) says.
ESA, the body responsible for the supervision of uranium supply and demand in the EU, warned that an increasing variety and volume of enriched isotopes will be needed for radionuclide production to support the development of new treatments in the fight against cancer.